GLP-1 receptor agonists and cardiovascular outcomes: evidence from MACE trials

When the FDA mandated cardiovascular outcomes trials (CVOTs) for all new diabetes medications in 2008 — following safety concerns about rosiglitazone — the expectation was that manufacturers would demonstrate non-inferiority: that their drugs did not increase cardiovascular risk. What the GLP-1 receptor agonist trials actually demonstrated was superiority: meaningful reductions in cardiovascular events in high-risk patients, independent of their glucose-lowering effects.

This was not anticipated from the mechanism. GLP-1 receptor agonists were developed as metabolic agents targeting glucose control and weight. The cardiovascular benefits appear to reflect direct vascular and cardiac effects operating through pathways distinct from glycaemic improvement.

The MACE endpoint framework

The primary endpoint across cardiovascular outcomes trials is three-point MACE (Major Adverse Cardiovascular Events): a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. This endpoint was selected as clinically meaningful, verifiable, and appropriately powered for large trial designs.

All major GLP-1 RA CVOTs enrolled patients with established cardiovascular disease or high cardiovascular risk as an entry criterion, ensuring adequate event rates to detect differences.

LEADER trial: liraglutide

The LEADER trial enrolled 9,340 patients with type 2 diabetes and established cardiovascular disease or cardiovascular risk factors, randomised to liraglutide 1.8 mg/day or placebo (Marso et al., New England Journal of Medicine, 2016).

Key results at median 3.8 years follow-up:

• 3-point MACE: 13.0% liraglutide vs 14.9% placebo — hazard ratio 0.87 (95% CI 0.78–0.97), p=0.01 for superiority
• Cardiovascular death: Significant reduction (4.7% vs 6.0%, HR 0.78)
• All-cause mortality: Significant reduction (8.2% vs 9.6%, HR 0.85)
• Non-fatal MI: Numerical reduction, not statistically significant in isolation
• Non-fatal stroke: No significant difference

The cardiovascular death reduction was the primary driver of the overall MACE benefit in LEADER — a pattern that recurred in subsequent trials and has informed mechanistic hypotheses.

SUSTAIN-6: semaglutide

SUSTAIN-6 enrolled 3,297 patients with type 2 diabetes, randomised to once-weekly semaglutide (0.5 mg or 1 mg) or placebo (Marso et al., New England Journal of Medicine, 2016). Despite a shorter follow-up (2.1 years) and smaller sample, the results were striking:

• 3-point MACE: 6.6% semaglutide vs 8.9% placebo — HR 0.74 (95% CI 0.58–0.95), p=0.02 for superiority
• Non-fatal stroke: Significant reduction (1.6% vs 2.7%, HR 0.61) — the most pronounced stroke reduction seen in any GLP-1 RA trial
• Non-fatal MI: Numerical reduction, not statistically significant

The SUSTAIN-6 stroke reduction was notably larger than seen with other GLP-1 RAs, though this may partly reflect statistical variability in a smaller trial.

REWIND: dulaglutide

REWIND had a more inclusive design than earlier CVOTs — approximately 69% of participants had multiple cardiovascular risk factors but no established cardiovascular disease, making it most representative of the broader type 2 diabetes population (Gerstein et al., Lancet, 2019).

• 3-point MACE: 12.0% dulaglutide vs 13.4% placebo — HR 0.88 (95% CI 0.79–0.99), p=0.026 for superiority
• Benefit was consistent across primary and secondary prevention subgroups — suggesting cardiovascular protection extends to lower-risk patients

SELECT trial: semaglutide in non-diabetic obesity

The SELECT trial fundamentally reframed the GLP-1 cardiovascular story (Lincoff et al., New England Journal of Medicine, 2023). It enrolled 17,604 patients with overweight or obesity and established cardiovascular disease but without diabetes — the first major CVOT to test a GLP-1 RA in a non-diabetic population.

• 3-point MACE: 6.5% semaglutide vs 8.0% placebo — HR 0.80 (95% CI 0.72–0.90), p<0.001
• Benefit emerged within the first year and continued to diverge over the 33-month follow-up
• The effect was consistent across subgroups by BMI, sex, age, and baseline cardiovascular risk

SELECT's significance: cardiovascular protection from semaglutide in non-diabetic patients removes improved glycaemic control as a necessary mechanism, pointing to weight loss, direct vascular effects, or both as primary drivers.

Proposed mechanisms of cardiovascular protection

The cardiovascular benefits of GLP-1 RAs appear to be mediated through multiple parallel pathways rather than a single dominant mechanism.

Direct cardiac and vascular GLP-1R effects: GLP-1 receptors are expressed on cardiomyocytes, endothelial cells, and vascular smooth muscle. Activation reduces oxidative stress, attenuates inflammatory signalling (NF-κB pathway), and improves endothelial nitric oxide synthase (eNOS) activity — improving vasodilation and reducing atherogenic endothelial activation.

Atherosclerotic plaque stabilisation: GLP-1 RAs reduce macrophage foam cell formation in plaques and shift macrophage polarisation toward anti-inflammatory (M2) phenotypes. This plaque-stabilising effect may reduce vulnerability to rupture — the event triggering most acute coronary syndromes — and could explain why cardiovascular death is reduced even before structural plaque regression is demonstrable.

Blood pressure reduction: GLP-1 RAs consistently reduce systolic blood pressure by 2–4 mmHg. While modest, blood pressure reduction at population scale has established cardiovascular benefits and operates independently of glucose control.

Weight loss: Sustained 5–15% body weight reduction reduces cardiac preload and afterload, decreases ectopic fat deposition (pericardial and epicardial fat), and reduces inflammation driven by adipose tissue dysfunction. The SELECT trial results support weight-related mechanisms as significant contributors.

Anti-inflammatory effects: GLP-1 RAs reduce circulating CRP, IL-6, and TNF-α across clinical trials. Inflammation is a primary driver of atherosclerotic progression, connecting to the broader inflammaging and NAD+/sirtuin signalling research.

Renal protection: GLP-1 RAs reduce albuminuria and slow eGFR decline. Improved renal function reduces cardiovascular risk through reduced fluid overload and reduced uraemic pro-inflammatory signals.

Atrial fibrillation signal

An emerging finding across multiple GLP-1 RA datasets is a reduction in atrial fibrillation incidence — approximately 20% relative risk reduction in a meta-analysis of CVOTs. The proposed mechanism involves reduced left atrial pressure and size through weight loss and reduced cardiac filling pressures, alongside direct anti-fibrotic effects on atrial myocardium.

Context within the GLP-1 evidence base

This article focuses on cardiovascular outcomes. The mechanistic basis of GLP-1 receptor agonism — glucose control, gastric emptying, and appetite suppression — is covered in the GLP-1 receptor agonists explained article. For weight loss mechanisms specifically, see the semaglutide weight loss mechanisms article.

Summary

GLP-1 receptor agonists demonstrate consistent, statistically significant reductions in 3-point MACE across LEADER, SUSTAIN-6, REWIND, and SELECT. The SELECT trial's non-diabetic population removes glycaemic improvement as a necessary mediator, supporting direct cardiometabolic mechanisms as primary drivers. These mechanisms include direct vascular GLP-1R effects, plaque stabilisation, blood pressure reduction, weight loss, and systemic anti-inflammatory activity — a multi-pathway profile that distinguishes GLP-1 RA cardiovascular protection from single-mechanism interventions.